{
    "2020-02-22": [
        [
            {
                "time": "2019-09-20",
                "original_text": "FDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients",
                "features": {
                    "keywords": [
                        "FDA",
                        "approves",
                        "Trulicity",
                        "cardiovascular",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-09-20",
                "original_text": "TrulicityÂ® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease",
                "features": {
                    "keywords": [
                        "Trulicity",
                        "dulaglutide",
                        "first",
                        "reduce",
                        "cardiovascular events"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-09-20",
                "original_text": "U.S. FDA approves Lundbeck's migraine prevention therapy",
                "features": {
                    "keywords": [
                        "FDA",
                        "approves",
                        "Lundbeck",
                        "migraine",
                        "prevention"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}